Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Phys Chem Phys 25:22342247
But "future" is the key word
Significant global hypotonia, poor Moro reflex, poor suck reflex, weak cry Feeding difficulties that often require special feeding techniques Breathing difficulties including obstructive sleep apnea, central sleep apnea, and hypoventilation Characteristic facial features: almond-shaped eyes, narrow forehead, small down-turned mouth with thin upper lip Hypogonadism: small genitalia in males and females, undescended testes in males Hypopigmentation: fair coloring compared to family members Hip dysplasia, scoliosis Excessive daytime sleepiness Eye abnormalities including strabismus (usually estropia) Clinical Symptoms in Young Children without intervention: Global developmental delays Cognitive impairment, learning disorders Eye abnormalities including strabismus (estropia), amblyopia, myopia Excessive daytime sleepiness, narcolepsy, cataplexy Weight gain without an increase in calories (2 - 4.5 years) Hyperphagia: insatiable drive to eat, lack of normal satiety
Peel off the protective backing and firmly press the patch onto your skin
